Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Beyond Air Inc - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
XAIR
Nasdaq
3841
https://www.beyondair.net/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Beyond Air Inc
Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting
- May 1st, 2024 11:00 am
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
- Mar 20th, 2024 1:00 pm
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024
- Feb 12th, 2024 9:05 pm
Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast
- Jan 18th, 2024 1:00 pm
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors
- Dec 27th, 2023 12:30 pm
Beyond Air Independent Director Acquires 102% More Stock
- Dec 23rd, 2023 12:10 pm
Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air Inc
- Dec 21st, 2023 6:40 am
Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference
- Nov 15th, 2023 9:05 pm
Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024
- Nov 13th, 2023 9:05 pm
Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
- Nov 3rd, 2023 4:00 pm
Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast
- Oct 19th, 2023 8:05 pm
Beyond Air® To Participate in the Truist Securities BioPharma Symposium
- Oct 17th, 2023 8:05 pm
Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice
- Oct 17th, 2023 11:30 am
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Oct 16th, 2023 11:30 am
Beyond Air® Receives Innovative Technology Contract from Vizient for LungFit®PH
- Oct 16th, 2023 11:00 am
Beyond Cancer™ Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Oct 4th, 2023 11:30 am
Beyond Air® To Participate in the Roth MKM 2023 Healthcare Opportunities Conference
- Oct 2nd, 2023 8:05 pm
Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting
- Sep 27th, 2023 1:00 pm
Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder
- Sep 18th, 2023 8:05 pm
Beyond Air Insiders Placed Bullish Bets Worth US$2.3m
- Sep 15th, 2023 10:26 am
Scroll